NCT05340257View on ClinicalTrials.gov

A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 14, 2023

Primary Completion Date

July 8, 2024

Study Completion Date

July 8, 2024

Conditions

Infections, Bacterial

Interventions

DRUG

Augmentin ES

Amoxicillin and clavulanic acid in fixed dose combination will be administered

Trial Locations (2)

1223001

GSK Investigational Site, São Paulo

14051-140

GSK Investigational Site, Ribeirão Preto

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT05340257 - A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS | Biotech Hunter | Biotech Hunter